[1]

Sheeladevi S, Lawrenson JG, Fielder AR, Suttle CM. 2016. Global prevalence of childhood cataract: a systematic review. Eye 30:1160−1169

doi: 10.1038/eye.2016.156
[2]

AlObaisi S, Alnasser BN, Almuhawas HA, Alhoshan SA, Aldebasi MH, et al. 2024. Understanding post-operative refractive outcome in pediatrics after IOL implementation: factors and predictors. International Ophthalmology 44:364

doi: 10.1007/s10792-024-03280-w
[3]

Oshika T, Nishina S, Ura S, Miyagi M, Nomura K, et al. 2025. Long-term refractive changes after pediatric cataract surgery: an average follow-up of 15 years. American Journal of Ophthalmology 277:305−312

doi: 10.1016/j.ajo.2025.05.035
[4]

Li Y, Tan Y, Xu C, Jin G, Chen H, et al. 2024. Association between preoperative ocular parameters and myopic shift in children undergoing primary intraocular lens implantation. Translational Vision Science & Technology 13:24

doi: 10.1167/tvst.13.5.24
[5]

Li Y, Jin G, Tan Y, Chen H, Jin J, et al. 2025. Myopic shift after primary intraocular lens implantation in unilateral cataract children and its association with preoperative ocular parameters. Journal of Cataract and Refractive Surgery 51:53−59

doi: 10.1097/j.jcrs.0000000000001557
[6]

Zadnik K, Schulman E, Flitcroft I, Fogt JS, Blumenfeld LC, et al. 2023. Efficacy and safety of 0.01% and 0.02% atropine for the treatment of pediatric myopia progression over 3 years: a randomized clinical trial. JAMA Ophthalmology 141:990−999

doi: 10.1001/jamaophthalmol.2023.2097
[7]

Thomson K, Karouta C, Weber D, Hoffmann N, Morgan I, et al. 2023. The role of the serotonergic system in atropine’s anti-myopic effects. Biomedicine & Pharmacotherapy 167:115542

doi: 10.1016/j.biopha.2023.115542
[8]

Mitsukawa T, Suzuki Y, Momota Y, Suzuki S, Yamada M. 2021. Effects of 0.01% atropine instillation assessed using swept-source anterior segment optical coherence tomography. Journal of Clinical Medicine 10:4384

doi: 10.3390/jcm10194384
[9]

Chia A, Lu QS, Tan D. 2016. Five-year clinical trial on atropine for the treatment of myopia 2: myopia control with atropine 0.01% eyedrops. Ophthalmology 123:391−399

doi: 10.1016/j.ophtha.2015.07.004
[10]

Yam JC, Jiang Y, Tang SM, Law AKP, Chan JJ, et al. 2019. Low-concentration atropine for myopia progression (LAMP) study: a randomized, double-blinded, placebo-controlled trial of 0.05%, 0.025%, and 0.01% atropine eye drops in myopia control. Ophthalmology 126:113−124

doi: 10.1016/j.ophtha.2018.05.029
[11]

Chen D, Gong XH, Xie H, Zhu XN, Li J, et al. 2017. The long-term anterior segment configuration after pediatric cataract surgery and the association with secondary glaucoma. Scientific Reports 7:43015

doi: 10.1038/srep43015
[12]

Kumar P, Saxena R, Dhiman R, Phuljhele S, Kumar V, et al. 2023. Evaluation of the levels of low-dose topical atropine (0.01%) in aqueous and vitreous humor in human eyes. Optometry and Vision Science 100:530−536

doi: 10.1097/opx.0000000000002044
[13]

Wang Y, Zhu X, Xuan Y, Wang M, Zhou X, et al. 2022. Short-term effects of atropine 0.01% on the structure and vasculature of the choroid and retina in myopic Chinese children. Ophthalmology and Therapy 11:833−856

doi: 10.1007/s40123-022-00476-0
[14]

Wu J, Gong H, Li H, Liang J, Zhang X, et al. 2023. Changes in choroidal thickness in myopic children with 0.01% atropine: evidence from a 12-month follow-up. Photodiagnosis and Photodynamic Therapy 42:103528

doi: 10.1016/j.pdpdt.2023.103528
[15]

Liu F, Ye Y, Yang W, Wang J, Xu Y, et al. 2024. Quantitative evaluation of the topographical maps of three-dimensional choroidal vascularity index in children with different degrees of myopia. Investigative Ophthalmology & Visual Science 65:14

doi: 10.1167/iovs.65.3.14
[16]

Yang Y, Luo Z, Wen L, Gao W, Deng Y, et al. 2026. Short-term choroidal and retinal structural changes in myopic children treated with 0.05% atropine. Clinical Ophthalmology 20:570502

doi: 10.2147/opth.s570502
[17]

Tsai TH, Huang YC, Yeung L, Chuang LH, Chen HC, et al. 2025. Evaluating the effect of 0.125% atropine on foveal microvasculature using optical coherence tomography angiography. Scientific Reports 15:5970

doi: 10.1038/s41598-025-88025-0
[18]

Atchison DA. 2006. Optical models for human myopic eyes. Vision Research 46:2236−2250

doi: 10.1016/j.visres.2006.01.004
[19]

Wildsoet CF, Chia A, Cho P, Guggenheim JA, Polling JR, et al. 2019. IMI–interventions for controlling myopia onset and progression report. Investigative Ophthalmology & Visual Science 60:M106

doi: 10.1167/iovs.18-25958
[20]

Dubucs C, Caillet A, Frémont F, Delteil L, N'Go V, et al. 2024. Prevalence of congenital ocular anomalies in 15 countries of Europe: results from the medikeye study. Birth Defects Research 116:e2414

doi: 10.1002/bdr2.2414
[21]

Koc F, Kargi S, Biglan AW, Chu CT, Davis JS. 2006. The aetiology in paediatric aphakic glaucoma. Eye 20:1360−1365

doi: 10.1038/sj.eye.6702150
[22]

Coleman DJ, Fish SK. 2001. Presbyopia, accommodation, and the mature catenary. Ophthalmology 108:1544−1551

doi: 10.1016/S0161-6420(01)00691-1
[23]

Gharieb Ibrahim HM. 2022. Effect of pharmacological mydriasis on the intraocular pressure in eyes with filtering blebs compared to normal eyes: a pilot study. Clinical Ophthalmology 16:231−237

doi: 10.2147/OPTH.S348365
[24]

Lal B, Ostrin LA. 2026. Short-term effects of atropine on the retina and choroid in young adults. Eye and Vision 13:8

doi: 10.1186/s40662-026-00477-1
[25]

Sezgin Akcay BI, Gunay BO, Kardes E, Unlu C, Ergin A. 2016. Evaluation of the ganglion cell complex and retinal nerve fiber layer in low, moderate, and high myopia: a study by RTVue spectral domain optical coherence tomography. Seminars in Ophthalmology 32:682−688

doi: 10.3109/08820538.2016.1170157
[26]

Yang Y, Wei L, Wang B, Zheng W. 2024. Effects of atropine on choroidal thickness in myopic children: a meta-analysis. Frontiers in Pharmacology 15:1440180

doi: 10.3389/fphar.2024.1440180
[27]

Parida S, Das M, Dash S, Chakraborty S, Mohanty S, et al. 2025. Effect of low-dose atropine on choroidal thickness in children with myopia progression. Cureus 17:e88047

doi: 10.7759/cureus.88047
[28]

Yam JC, Jiang Y, Lee J, Li S, Zhang Y, et al. 2022. The association of choroidal thickening by atropine with treatment effects for myopia: two-year clinical trial of the low-concentration atropine for myopia progression (LAMP) study. American Journal of Ophthalmology 237:130−138

doi: 10.1016/j.ajo.2021.12.014
[29]

Tan CS, Ouyang Y, Ruiz H, Sadda SR. 2012. Diurnal variation of choroidal thickness in normal, healthy subjects measured by spectral domain optical coherence tomography. Investigative Ophthalmology & Visual Science 53:261−266

doi: 10.1167/iovs.11-8782
[30]

Hoseini-Yazdi H, Vincent SJ, Collins MJ, Read SA, Alonso-Caneiro D. 2019. Repeatability of wide-field choroidal thickness measurements using enhanced-depth imaging optical coherence tomography. Clinical & Experimental Optometry 102:327−334

doi: 10.1111/cxo.12893
[31]

Kinoshita T, Mitamura Y, Shinomiya K, Egawa M, Iwata A, et al. 2017. Diurnal variations in luminal and stromal areas of choroid in normal eyes. The British Journal of Ophthalmology 101:360−364

doi: 10.1136/bjophthalmol-2016-308594
[32]

Zhu Q, Xing X, Ma L, Yuan Y, Song E. 2025. Three-dimensional choroidal parameter differences in myopic anisometropia. BMC Ophthalmology 25:583

doi: 10.1186/s12886-025-04425-w
[33]

Su N, Yuan X, Yin W, Huang K, Fan W, et al. 2026. Choroidal volume decrease associated with stromal regression in adult myopia: a high-resolution optical coherence tomography angiography study. Photodiagnosis and Photodynamic Therapy 57:105288

doi: 10.1016/j.pdpdt.2025.105288
[34]

Sander BP, Collins MJ, Read SA. 2014. The effect of topical adrenergic and anticholinergic agents on the choroidal thickness of young healthy adults. Experimental Eye Research 128:181−189

doi: 10.1016/j.exer.2014.10.003
[35]

Gupta S, Ramteke S, Chattannavar G, Kekunnaya R. 2024. Myopic shift, refractive, and visual outcomes after 5 years of infantile cataract surgery: our experience and review of literature. Taiwan Journal of Ophthalmology 14:236−241

doi: 10.4103/tjo.TJO-D-24-00030
[36]

Kur J, Newman EA, Chan-Ling T. 2012. Cellular and physiological mechanisms underlying blood flow regulation in the retina and choroid in health and disease. Progress in Retinal and Eye Research 31:377−406

doi: 10.1016/j.preteyeres.2012.04.004
[37]

Małyszczak A, Żyto M, Przeździecka-Dołyk J, Misiuk-Hojło M. 2023. Macular vascularity and ganglion cell complex parameters in the young adults with myopia and progressive myopia. Clinical Ophthalmology 17:561−570

doi: 10.2147/OPTH.S389963
[38]

Wang D, Zhang Y, Lin F, Song Y, Jin L, et al. 2024. Peripheral ganglion cell complex thickness and retinal microvasculature in myopia using wide-field swept-source OCT. Translational Vision Science & Technology 13:4

doi: 10.1167/tvst.13.8.4